{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:10:54Z","timestamp":1789762254912,"version":"4.0.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.annonc.2026.07.003","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:40:25Z","timestamp":1783698025000},"page":"1320-1321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Keeping the story, turning the page: from prognostic to predictive AI in high-risk prostate cancer"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7216-5706","authenticated-orcid":false,"given":"S.P.","family":"Mende","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Foersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.annonc.2026.07.003_bib1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate cancer, version 3.2026, NCCN clinical practice guidelines in oncology","volume":"23","author":"Spratt","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.annonc.2026.07.003_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/pcan.2013.46","article-title":"Very-high-risk localized prostate cancer: definition and outcomes","volume":"17","author":"Sundi","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.annonc.2026.07.003_bib3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41391-022-00621-7","article-title":"Revisiting current National Comprehensive Cancer Network (NCCN) high-risk prostate cancer stratification: a National Cancer Database analysis","volume":"27","author":"Garg","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.annonc.2026.07.003_bib4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrclinonc.2014.68","article-title":"High-risk prostate cancer-classification and therapy","volume":"11","author":"Chang","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2026.07.003_bib5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.clon.2019.04.012","article-title":"Who dies from prostate cancer? An analysis of the surveillance, epidemiology and end results database","volume":"31","author":"Roy","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"3","key":"10.1016\/j.annonc.2026.07.003_bib6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00345-008-0250-7","article-title":"High-risk prostate cancer in the United States, 1990-2007","volume":"26","author":"Cooperberg","year":"2008","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.annonc.2026.07.003_bib7","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1464-410X.2010.09594.x","article-title":"Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy","volume":"107","author":"Walz","year":"2011","journal-title":"BJU Int"},{"issue":"10323","key":"10.1016\/j.annonc.2026.07.003_bib8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.annonc.2026.07.003_bib9","volume":"7","author":"Parker","year":"2025","journal-title":"Lancet Digit Health"},{"issue":"10","key":"10.1016\/j.annonc.2026.07.003_bib11","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.annonc.2026.05.708","article-title":"Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer","volume":"37","author":"Parker","year":"2026","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.07.003_bib10","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.annonc.2025.11.009","article-title":"ESMO basic requirements for AI-based biomarkers in oncology (EBAI)","volume":"37","author":"Aldea","year":"2026","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426009993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426009993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:43:27Z","timestamp":1789760607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426009993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0923753426009993"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.07.003","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Keeping the story, turning the page: from prognostic to predictive AI in high-risk prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.05.708","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}